

Title (en)
PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS KONDENSIERTEM AMINODIHYDROTHIAZINDERIVAT

Title (fr)
COMPOSITION PHARMACEUTIQUE DE DÉRIVÉ D'AMINODIHYDROTHIAZINE FUSIONNÉ

Publication
EP 3205343 A4 20180606 (EN)

Application
EP 15848771 A 20151008

Priority
• JP 2014209289 A 20141010
• JP 2015078688 W 20151008

Abstract (en)
[origin: EP3205343A1] The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

IPC 8 full level
A61K 31/542 (2006.01); **A61K 9/20** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP IL KR RU US)
A61K 9/20 (2013.01 - IL KR); **A61K 9/2018** (2013.01 - EP IL US); **A61K 9/2054** (2013.01 - IL); **A61K 31/542** (2013.01 - EP IL KR RU US); **A61K 47/06** (2013.01 - IL RU); **A61K 47/14** (2013.01 - IL KR); **A61K 47/20** (2013.01 - IL KR); **A61P 25/00** (2017.12 - IL RU); **A61P 25/28** (2017.12 - EP IL US); **A61K 9/2054** (2013.01 - US)

Citation (search report)
• [X] US 2014271911 A1 20140918 - WALLACE JAMES [US]
• [XY] EP 2233474 A1 20100929 - EISAI R&D MAN CO LTD [JP]
• [XY] ANONYMOUS: "Study Record NCT01716897 - A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults Secondary IDs", CLINICALTRIALS.GOV, 20 March 2012 (2012-03-20), XP055471357, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01716897?V_4=View#StudyPageTop> [retrieved on 20180428]
• [XY] ANONYMOUS: "NCT02222324 - A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, 4-Treatment Crossover Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects Secondary", CLINICALTRIALS.GOV, 19 August 2014 (2014-08-19), XP055471355, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT02222324?V_1=View#StudyPageTop> [retrieved on 20180427]
• [Y] KIBBE A H ED - KIBBE A H (ED): "Handbook of Pharmaceutical Excipients, MAGNESIUM STEARATE", 1 January 2000, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, AMERICAN PHARMACEUTICAL ASSOC. [U.A.], WASHINGTON, DC; US, PAGE(S) 305,276,102,528,87,433, ISBN: 978-0-85369-381-9, XP002209938
• See references of WO 2016056638A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
EP 3205343 A1 20170816; EP 3205343 A4 20180606; EP 3205343 B1 20220126; AU 2015329027 A1 20170427; AU 2015329027 B2 20200430; BR 112017007293 A2 20171226; BR 112017007293 B1 20221213; CA 2963761 A1 20160414; CA 2963761 C 20231017; CN 107106568 A 20170829; CN 107106568 B 20230926; ES 2909797 T3 20220510; IL 251559 A0 20170529; IL 251559 B 20210228; JP 2019196395 A 20191114; JP 2020125330 A 20200820; JP 6590822 B2 20191016; JP WO2016056638 A1 20170720; KR 102524217 B1 20230421; KR 20170066397 A 20170614; MX 2017004418 A 20170626; MX 370338 B 20191210; RU 2017111801 A 20181113; RU 2017111801 A3 20190212; RU 2710227 C2 20191225; SG 11201702632Q A 20170530; US 10117876 B2 20181106; US 2018263998 A1 20180920; WO 2016056638 A1 20160414

DOCDB simple family (application)
EP 15848771 A 20151008; AU 2015329027 A 20151008; BR 112017007293 A 20151008; CA 2963761 A 20151008; CN 201580055101 A 20151008; ES 15848771 T 20151008; IL 25155917 A 20170404; JP 2015078688 W 20151008; JP 2016553160 A 20151008; JP 2019137458 A 20190726; JP 2020075659 A 20200421; KR 20177009221 A 20151008; MX 2017004418 A 20151008; RU 2017111801 A 20151008; SG 11201702632Q A 20151008; US 201515516567 A 20151008